A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Acetylcysteine (Primary) ; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PANORAMA
  • Sponsors InterMune; Roche
  • Most Recent Events

    • 21 Sep 2015 According to a Roche media release, data from this trial will be presented at the European Respiratory Society Congress 2015.
    • 15 Aug 2015 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
    • 17 Oct 2013 New source identified and integrated (United Kingdom Clinical Research Network record, 15192).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top